Overview

Controlled Trial on Effect of Montelukast Treatment in Children With Obstructive Sleep Apnea Syndrome

Status:
Withdrawn
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Oral therapy with montelukast may lead to improved polysomnographic findings in children with mild to moderate OSAS with and without allergic rhinitis who a priori require T&A for OSAS. - A significant proportion of the children with OSAS treated with montelukast will show reduced severity of OSAS, and this will obviate the need for surgical T&A.
Phase:
Phase 2
Details
Lead Sponsor:
University of Louisville
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Montelukast